Intracranial self-stimulation reverses impaired spatial learning and regulates serum microRNA levels in a streptozotocin-induced rat model of Alzheimer disease
CONCLUSION: Spatial memory performance, hippocampal neurodegeneration, and serum levels of miR-let-7b and miR-181c were affected by MFB-ICSS under AD-like conditions. Our results validate the MFB as a potential target for DBS and lend support to the use of specific miRNAs as promising biomarkers of the effectiveness of DBS in combatting AD-associated cognitive deficits.PMID:38490646 | DOI:10.1503/jpn.230066 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 15, 2024 Category: Psychiatry Authors: Andrea Riberas-S ánchez Irene Puig-Parnau Laia Vila-Sol és Soleil Garcia-Brito Laura Aldavert-Vera Pilar Segura-Torres Gemma Huguet Elisabet K ádár Source Type: research

Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models
J Psychiatry Neurosci. 2024 Mar 15;49(2):E109-E125. doi: 10.1503/jpn.230112. Print 2024 Jan-Feb.ABSTRACTThe pathophysiology of schizophrenia and bipolar disorder involves a complex interaction between genetic and environmental factors that begins in the early stages of neurodevelopment. Recent advancements in the field of induced pluripotent stem cells (iPSCs) offer a promising tool for understanding the neurobiological alterations involved in these disorders and, potentially, for developing new treatment options. In this review, we summarize the results of iPSC-based research on schizophrenia and bipolar disorder, showing...
Source: Journal of Psychiatry and Neuroscience - March 15, 2024 Category: Psychiatry Authors: Andrea Perrottelli Francesco Flavio Marzocchi Edoardo Caporusso Giulia Maria Giordano Luigi Giuliani Antonio Melillo Pasquale Pezzella Paola Bucci Armida Mucci Silvana Galderisi Source Type: research

Intracranial self-stimulation reverses impaired spatial learning and regulates serum microRNA levels in a streptozotocin-induced rat model of Alzheimer disease
CONCLUSION: Spatial memory performance, hippocampal neurodegeneration, and serum levels of miR-let-7b and miR-181c were affected by MFB-ICSS under AD-like conditions. Our results validate the MFB as a potential target for DBS and lend support to the use of specific miRNAs as promising biomarkers of the effectiveness of DBS in combatting AD-associated cognitive deficits.PMID:38490646 | DOI:10.1503/jpn.230066 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 15, 2024 Category: Psychiatry Authors: Andrea Riberas-S ánchez Irene Puig-Parnau Laia Vila-Sol és Soleil Garcia-Brito Laura Aldavert-Vera Pilar Segura-Torres Gemma Huguet Elisabet K ádár Source Type: research

Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models
J Psychiatry Neurosci. 2024 Mar 15;49(2):E109-E125. doi: 10.1503/jpn.230112. Print 2024 Jan-Feb.ABSTRACTThe pathophysiology of schizophrenia and bipolar disorder involves a complex interaction between genetic and environmental factors that begins in the early stages of neurodevelopment. Recent advancements in the field of induced pluripotent stem cells (iPSCs) offer a promising tool for understanding the neurobiological alterations involved in these disorders and, potentially, for developing new treatment options. In this review, we summarize the results of iPSC-based research on schizophrenia and bipolar disorder, showing...
Source: Journal of Psychiatry and Neuroscience - March 15, 2024 Category: Psychiatry Authors: Andrea Perrottelli Francesco Flavio Marzocchi Edoardo Caporusso Giulia Maria Giordano Luigi Giuliani Antonio Melillo Pasquale Pezzella Paola Bucci Armida Mucci Silvana Galderisi Source Type: research

Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research

Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research

Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research

Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research

Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research

Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research

Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research

Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research

Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research

Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research

Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research